NYSE$BMY

Bristol-Myers Squibb Co · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Reported fourth quarter revenues of $11.4 billion and full-year revenues of $46.2 billion.

Bristol Myers Squibb reported a decrease in fourth-quarter revenues by 5% to $11.4 billion, driven by recent LOE products and foreign exchange impacts, which was partially offset by in-line products and new product portfolio. The company reported GAAP EPS of $0.95 and non-GAAP EPS of $1.82 for the quarter.

  • Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange
  • Fourth Quarter GAAP EPS was $0.95 and Non-GAAP EPS was $1.82, including Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
  • Full-Year GAAP EPS was $2.95 and Non-GAAP EPS was $7.70, including Net Impact of ($0.24) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
  • Provided GAAP and Non-GAAP Financial Guidance for 2023 Reflecting Continued Revenue and Earnings Growth

Headline financials

Total Revenue

$11.4B

Previous: $12B-4.8%
EPS (adj)

$1.82

Previous: $1.83-0.5%
Gross Margin

77.3%

Previous: 80.3%-3.7%
Capital Expenditures

$346M

Previous: $320M+8.1%
Free Cash Flow

$2.96B

Previous: $3.74B-20.8%
Net Income

$2.03B

Previous: $2.37B-14.6%
Operating Income

$1.86B

Previous: $1.86B+0.1%
Gross Profit

$8.81B

Previous: $9.63B-8.5%
Cash & Equivalents

$9.12B

Previous: $14B-34.7%
Total Assets

$96.8B

Previous: $17B+470.7%
Stock-Based Comp

$119M

Previous: $133M-10.5%

Revenue & EPS history

Bristol-Myers Squibb · Revenue · Quarterly

$11.4B

Q4 2022-4.8%vs Q4 2021
Beat estimate in 14 of 15 quarters(93%)
ActualEstimate

Forward guidance

Bristol Myers Squibb provides its 2023 GAAP EPS guidance range of $4.03 - $4.33 and its non-GAAP EPS guidance range of $7.95 - $8.25.

Tailwinds

  • Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange.
  • Revenues from Revlimid are expected to be approximately $6.5 billion.
  • Gross margin is expected to be approximately 77% for GAAP and for non-GAAP.
  • Operating expenses are expected to decrease by mid-single digits for GAAP and decrease by low single digits for non-GAAP.
  • An effective tax rate of approximately 22% for GAAP and approximately 17% for non-GAAP.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-0.1%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+0.9%

Avg return

30 days after

47%

34 / 73 earnings

Positive

+8.2%

Q2 2024

Best reaction

-9.9%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.9%-1.1%-0.7%
Q4 2025+3.3%+5.6%+4.6%
Q3 2025+7.1%+7.0%+15.5%
Q2 2025-5.8%-0.3%+2.6%
Q1 2025+0.4%+1.4%-3.5%
Q4 2024-3.8%-6.3%+2.3%
Q3 2024+3.2%+6.2%+12.5%
Q2 2024+8.2%+5.1%+6.3%
Q1 2024-8.2%-10.1%-15.6%
Q4 2023-1.4%-0.1%+4.6%
Q3 2023-9.9%-9.0%-12.1%
Q2 2023-3.2%-3.0%-2.1%
Q1 2023-1.8%+0.1%-6.2%
Q4 2022+4.5%+4.6%-2.7%
Q3 2022+2.0%+5.3%+8.4%
Q2 2022+1.5%-0.0%-3.3%
Q1 2022-2.7%-1.2%-1.4%
Q4 2021+3.3%+4.8%+8.3%
Q3 2021-1.9%+0.8%-2.9%
Q2 2021+1.0%+0.8%-1.3%
Q1 2021-5.5%-3.2%-0.5%
Q4 2020-1.8%-3.7%-2.6%
Q3 2020-2.5%-1.4%-4.8%
Q2 2020+2.2%+5.8%+0.4%
Q1 2020-0.1%+3.6%+0.3%
Q4 2019+1.0%+2.1%-8.1%
Q3 2019+0.5%-0.8%+0.1%
Q2 2019+5.0%+3.1%+7.7%
Q1 2019+2.8%+4.1%+4.9%
Q4 2018-2.1%-3.3%+2.0%
Q3 2018+3.3%+2.4%+8.4%
Q2 2018-3.6%-0.5%+1.6%
Q1 2018+1.0%+1.8%+2.0%
Q4 2017-4.1%-1.2%+4.1%
Q3 2017-6.3%-3.7%-4.0%
Q2 2017-1.3%+0.2%+4.3%
Q1 2017+4.2%+4.1%+0.4%
Q4 2016-3.7%-0.8%+13.9%
Q3 2016+3.5%+3.1%+15.6%
Q2 2016-2.2%-1.9%-23.1%
Q1 2016+2.8%
Q4 2015+0.7%
Q3 2015+4.7%
Q2 2015-4.9%
Q1 2015-1.3%
Q4 2014-1.8%
Q3 2014+2.0%
Q2 2014+0.1%
Q1 2014-0.5%
Q4 2013-7.8%
Q3 2013-0.7%
Q2 2013-0.8%
Q1 2013-2.8%
Q4 2012+5.1%
Q3 2012+1.5%
Q2 2012+3.1%
Q1 2012-0.6%
Q4 2011+0.9%
Q3 2011-1.3%
Q2 2011+0.2%
Q1 2011-0.0%
Q4 2010-1.5%
Q4 2007-1.5%
Q3 2010-1.1%
Q2 2010-0.4%
Q1 2009+4.0%
Q1 2010+0.7%
Q4 2009-0.6%
Q3 2008-2.0%
Q3 2009-2.0%
Q4 2008+5.5%
Q2 2008+5.5%
Q2 2009+5.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro